Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013

Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MI...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2017-08, Vol.214 (2), p.323-328
Main Authors: Thomas, Alexandra, MD, Weigel, Ronald J., MD, PhD, Lynch, Charles F., MD, PhD, Spanheimer, Philip M., MD, Breitbach, Elizabeth K., MD, Schroeder, Mary C., PhD
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Breast neoplasms
Breast Neoplasms - chemistry
Breast Neoplasms - epidemiology
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Cancer incidence
Carcinoma, Intraductal, Noninfiltrating - chemistry
Carcinoma, Intraductal, Noninfiltrating - epidemiology
Carcinoma, Intraductal, Noninfiltrating - pathology
Carcinoma, Intraductal, Noninfiltrating - therapy
Chemotherapy
Epidermal growth factor
Female
Humans
Incidence
Invasiveness
Iowa
Mammography
Mastectomy
Methyl isobutyl carbinol
Microinvasive tumor
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Receptor, ErbB-2 - analysis
SEER Program
Surgery
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3
cites cdi_FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3
container_end_page 328
container_issue 2
container_start_page 323
container_title The American journal of surgery
container_volume 214
creator Thomas, Alexandra, MD
Weigel, Ronald J., MD, PhD
Lynch, Charles F., MD, PhD
Spanheimer, Philip M., MD
Breitbach, Elizabeth K., MD
Schroeder, Mary C., PhD
description Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MIBC (Stage 1BC). Results From 2000-2013, 1,706, 193 and 4,514 women were diagnosed with DCIS, MIBC and Stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (p=0.041). MIBC was more frequently human epidermal-growth-factor-receptor-2 positive than Stage 1BC (39.7% vs 9.6%, p
doi_str_mv 10.1016/j.amjsurg.2016.08.008
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5334458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961016305049</els_id><sourcerecordid>1835352018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3</originalsourceid><addsrcrecordid>eNqFUsFu1DAQjRCIbgufALLEhUMT7DjOxhyKULXASpWQKJytiTPZOiT21k4W7Vf0l3HYpUAvnOzRvHkzb94kyQtGM0ZZ-abLYOjC5DdZHsOMVhml1aNkwaqlTFlV8cfJglKap7Jk9CQ5DaGLIWMFf5qc5MtS5kuZL5K7tdWmQavxnOgb8KBH9CaMRgcCtiEDWNjggHYkriUedfz1e9IY2FgXsDkng9HeBe22RkMfU8buIJgdktojhJFoiOSe1Ptf1dvReRJGGKfwlqzdDyDXq9UXksfZ0iiEP0uetNAHfH58z5JvH1ZfLz-lV58_ri_fX6VaCDqmZU3bAkpZCCigoELXGpFLrlnTIK85r2Rb6qKVqMslFbnUXAqBrOKsBN22_Cy5OPBup3rAZpbloVdbbwbwe-XAqH8z1tyojdspwXlRiCoSvD4SeHc7YRjVYILGvgeLbgoqthJcREkz9NUDaOcmb6M8xWSeV6LkchlR4oCa1xk8tvfDMKpmy1Wnjpar2XJFKxUtj3Uv_1ZyX_Xb4wh4dwBg3OfOoFdBm9nxxkRHRtU4898WFw8YdG_s7Pd33GP4o0aFXFF1Pd_dfHas5FTQQvKfATfWkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1922856397</pqid></control><display><type>article</type><title>Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013</title><source>ScienceDirect Journals</source><creator>Thomas, Alexandra, MD ; Weigel, Ronald J., MD, PhD ; Lynch, Charles F., MD, PhD ; Spanheimer, Philip M., MD ; Breitbach, Elizabeth K., MD ; Schroeder, Mary C., PhD</creator><creatorcontrib>Thomas, Alexandra, MD ; Weigel, Ronald J., MD, PhD ; Lynch, Charles F., MD, PhD ; Spanheimer, Philip M., MD ; Breitbach, Elizabeth K., MD ; Schroeder, Mary C., PhD</creatorcontrib><description>Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MIBC (Stage 1BC). Results From 2000-2013, 1,706, 193 and 4,514 women were diagnosed with DCIS, MIBC and Stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (p=0.041). MIBC was more frequently human epidermal-growth-factor-receptor-2 positive than Stage 1BC (39.7% vs 9.6%, p&lt;0.001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, p=0.014) or Stage 1BC (40.9% vs 33.8%, p=0.119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and Stage 1BC. Conclusions Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2016.08.008</identifier><identifier>PMID: 27692792</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biopsy ; Breast cancer ; Breast neoplasms ; Breast Neoplasms - chemistry ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer ; Cancer incidence ; Carcinoma, Intraductal, Noninfiltrating - chemistry ; Carcinoma, Intraductal, Noninfiltrating - epidemiology ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Intraductal, Noninfiltrating - therapy ; Chemotherapy ; Epidermal growth factor ; Female ; Humans ; Incidence ; Invasiveness ; Iowa ; Mammography ; Mastectomy ; Methyl isobutyl carbinol ; Microinvasive tumor ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Receptor, ErbB-2 - analysis ; SEER Program ; Surgery ; Womens health</subject><ispartof>The American journal of surgery, 2017-08, Vol.214 (2), p.323-328</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3</citedby><cites>FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3</cites><orcidid>0000-0002-1043-8140</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27692792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Alexandra, MD</creatorcontrib><creatorcontrib>Weigel, Ronald J., MD, PhD</creatorcontrib><creatorcontrib>Lynch, Charles F., MD, PhD</creatorcontrib><creatorcontrib>Spanheimer, Philip M., MD</creatorcontrib><creatorcontrib>Breitbach, Elizabeth K., MD</creatorcontrib><creatorcontrib>Schroeder, Mary C., PhD</creatorcontrib><title>Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MIBC (Stage 1BC). Results From 2000-2013, 1,706, 193 and 4,514 women were diagnosed with DCIS, MIBC and Stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (p=0.041). MIBC was more frequently human epidermal-growth-factor-receptor-2 positive than Stage 1BC (39.7% vs 9.6%, p&lt;0.001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, p=0.014) or Stage 1BC (40.9% vs 33.8%, p=0.119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and Stage 1BC. Conclusions Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.</description><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast neoplasms</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer</subject><subject>Cancer incidence</subject><subject>Carcinoma, Intraductal, Noninfiltrating - chemistry</subject><subject>Carcinoma, Intraductal, Noninfiltrating - epidemiology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - therapy</subject><subject>Chemotherapy</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Invasiveness</subject><subject>Iowa</subject><subject>Mammography</subject><subject>Mastectomy</subject><subject>Methyl isobutyl carbinol</subject><subject>Microinvasive tumor</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>SEER Program</subject><subject>Surgery</subject><subject>Womens health</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFUsFu1DAQjRCIbgufALLEhUMT7DjOxhyKULXASpWQKJytiTPZOiT21k4W7Vf0l3HYpUAvnOzRvHkzb94kyQtGM0ZZ-abLYOjC5DdZHsOMVhml1aNkwaqlTFlV8cfJglKap7Jk9CQ5DaGLIWMFf5qc5MtS5kuZL5K7tdWmQavxnOgb8KBH9CaMRgcCtiEDWNjggHYkriUedfz1e9IY2FgXsDkng9HeBe22RkMfU8buIJgdktojhJFoiOSe1Ptf1dvReRJGGKfwlqzdDyDXq9UXksfZ0iiEP0uetNAHfH58z5JvH1ZfLz-lV58_ri_fX6VaCDqmZU3bAkpZCCigoELXGpFLrlnTIK85r2Rb6qKVqMslFbnUXAqBrOKsBN22_Cy5OPBup3rAZpbloVdbbwbwe-XAqH8z1tyojdspwXlRiCoSvD4SeHc7YRjVYILGvgeLbgoqthJcREkz9NUDaOcmb6M8xWSeV6LkchlR4oCa1xk8tvfDMKpmy1Wnjpar2XJFKxUtj3Uv_1ZyX_Xb4wh4dwBg3OfOoFdBm9nxxkRHRtU4898WFw8YdG_s7Pd33GP4o0aFXFF1Pd_dfHas5FTQQvKfATfWkw</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Thomas, Alexandra, MD</creator><creator>Weigel, Ronald J., MD, PhD</creator><creator>Lynch, Charles F., MD, PhD</creator><creator>Spanheimer, Philip M., MD</creator><creator>Breitbach, Elizabeth K., MD</creator><creator>Schroeder, Mary C., PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1043-8140</orcidid></search><sort><creationdate>20170801</creationdate><title>Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013</title><author>Thomas, Alexandra, MD ; Weigel, Ronald J., MD, PhD ; Lynch, Charles F., MD, PhD ; Spanheimer, Philip M., MD ; Breitbach, Elizabeth K., MD ; Schroeder, Mary C., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast neoplasms</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer</topic><topic>Cancer incidence</topic><topic>Carcinoma, Intraductal, Noninfiltrating - chemistry</topic><topic>Carcinoma, Intraductal, Noninfiltrating - epidemiology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - therapy</topic><topic>Chemotherapy</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Invasiveness</topic><topic>Iowa</topic><topic>Mammography</topic><topic>Mastectomy</topic><topic>Methyl isobutyl carbinol</topic><topic>Microinvasive tumor</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>SEER Program</topic><topic>Surgery</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Alexandra, MD</creatorcontrib><creatorcontrib>Weigel, Ronald J., MD, PhD</creatorcontrib><creatorcontrib>Lynch, Charles F., MD, PhD</creatorcontrib><creatorcontrib>Spanheimer, Philip M., MD</creatorcontrib><creatorcontrib>Breitbach, Elizabeth K., MD</creatorcontrib><creatorcontrib>Schroeder, Mary C., PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Alexandra, MD</au><au>Weigel, Ronald J., MD, PhD</au><au>Lynch, Charles F., MD, PhD</au><au>Spanheimer, Philip M., MD</au><au>Breitbach, Elizabeth K., MD</au><au>Schroeder, Mary C., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>214</volume><issue>2</issue><spage>323</spage><epage>328</epage><pages>323-328</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MIBC (Stage 1BC). Results From 2000-2013, 1,706, 193 and 4,514 women were diagnosed with DCIS, MIBC and Stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (p=0.041). MIBC was more frequently human epidermal-growth-factor-receptor-2 positive than Stage 1BC (39.7% vs 9.6%, p&lt;0.001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, p=0.014) or Stage 1BC (40.9% vs 33.8%, p=0.119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and Stage 1BC. Conclusions Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27692792</pmid><doi>10.1016/j.amjsurg.2016.08.008</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1043-8140</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9610
ispartof The American journal of surgery, 2017-08, Vol.214 (2), p.323-328
issn 0002-9610
1879-1883
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5334458
source ScienceDirect Journals
subjects Biopsy
Breast cancer
Breast neoplasms
Breast Neoplasms - chemistry
Breast Neoplasms - epidemiology
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Cancer incidence
Carcinoma, Intraductal, Noninfiltrating - chemistry
Carcinoma, Intraductal, Noninfiltrating - epidemiology
Carcinoma, Intraductal, Noninfiltrating - pathology
Carcinoma, Intraductal, Noninfiltrating - therapy
Chemotherapy
Epidermal growth factor
Female
Humans
Incidence
Invasiveness
Iowa
Mammography
Mastectomy
Methyl isobutyl carbinol
Microinvasive tumor
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Receptor, ErbB-2 - analysis
SEER Program
Surgery
Womens health
title Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence,%20characteristics%20and%20management%20of%20recently%20diagnosed,%20microscopically%20invasive%20breast%20cancer%20by%20receptor%20status:%20Iowa%20SEER%202000-2013&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Thomas,%20Alexandra,%20MD&rft.date=2017-08-01&rft.volume=214&rft.issue=2&rft.spage=323&rft.epage=328&rft.pages=323-328&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2016.08.008&rft_dat=%3Cproquest_pubme%3E1835352018%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c550t-6b0f4a6945a4a405cbcee393c1dde3b3389f6c4f9ec670529c3955e18316acff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1922856397&rft_id=info:pmid/27692792&rfr_iscdi=true